Market Overview

UPDATE: Sarepta Downgraded by Citigroup on Eteplirsen Early Approval Setback


In a report published Monday, Citigroup analysts Yaron Werber and Jonathan Eckard downgraded Sarepta Therapeutics (NASDAQ: SRPT) from a NEUTRAL to SELL, adjusting the price target to $13.

The Citigroup analysts noted, “..we do not anticipate that FDA will reverse its view that eteplirsen's ph 2 data is not sufficient to file. We expect eteplirsen's approval will be delayed until at least ‘17. We view the path ahead as being risky, lengthy and expensive and the recent strong stock rebound on hopes for early filing is overdone.”

SRPT closed previously on Friday at $20.44 and is currently trading around $18.02.

Posted-In: Downgrades Price Target Analyst Ratings


Related Articles (SRPT)

View Comments and Join the Discussion!

Latest Ratings

AAPLWedbushInitiates Coverage On310.0
DHTJP MorganUpgrades0.0
DXCMGoldman SachsUpgrades125.0
ORLYJP MorganUpgrades398.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

The Next Big Thing: Smartwatches?

Morgan Stanley Upgrades Abbott Based on Reacceleration